GlucoTrack announces study of CBGM met all primary endpoints

Glucotrack (GCTK) announced results from its completed first-in-human clinical study presented at the American Diabetes Association’s, ADA, 85th Scientific Sessions, which took place June 20-23, 2025, in Chicago. The study met all primary and secondary endpoints, demonstrating excellent accuracy with a Mean Absolute Relative Difference, MARD, of 7.7% across 122 matched pairs, a 99% data capture rate, and no procedure or device-related serious adverse events. These findings validate the safety and performance of the Company’s long-term, implantable Continuous Blood Glucose Monitor, CBGM, which measures glucose from blood rather than interstitial fluid, eliminating the typical lag time associated with traditional continuous glucose monitoring systems. These results were presented on June 21 to a standing room only crowd in the Innovation Hub of the Exhibit Hall at the ADA meeting.